Selective Embolization with N-butyl Cyanoacrylate for Metastatic Bone Disease

Rossi, Giuseppe; Mavrogenis, Andreas F.; Rimondi, Eugenio; Braccaioli, Lucia; Calabrò, Teresa; Ruggieri, Pietro

doi:10.1016/j.jvir.2010.12.023

Cited by 47 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this palliative effect is transient; symptoms recurred after 8.1 months [37][38]. However, this palliative effect is transient; symptoms recurred after 8.1 months [37][38].…”

Section: Resultsmentioning

confidence: 99%

“…Life expectancy is not influenced by embolization therapy and embolization therapy does not appear to improve survival [38]. However, embolization has an important impact on palliation and quality of life.…”

Section: Resultsmentioning

confidence: 99%

“…Indication for embolization of bone metastases is palliation including control of hemorrhage, facilitation of subsequent surgery, inhibition of tumor growth, and relief of pain secondary to decrease in tumor volume and pressure on the richly innervated periosteum and adjacent structures [12][13][33][34][35][36]; indications for repeat embolization are pain and/or imaging evidence of progressive disease [37][38]. Preoperative or serial embolization techniques using gelfoam, PVA particles, alcohol emulsions, coils, tissue adhesives, ethanol, and microfibrillar collagen can be used as primary or adjuvant treatment to surgery or radiation therapy [39].…”

Section: Palliative Embolizationmentioning

confidence: 99%

“…In patients with metastases in the pelvis or lower extremities, the contralateral transfemoral access is used ( Figure 1). In our practice, N-2-Butyl Cyano-Acrylate (NBCA, Glubran 2, GEM, Viareggio, Italy) was the preferred embolic agent because we consider the most appropriate embolic agent for controlled and permanent occlusion of the target vessels and tumor devascularization [37][38]. In patients with extremity lesions (Figure 2), aortography is not performed.…”

Section: Techniquementioning

confidence: 99%

See 3 more Smart Citations

Modern Palliative Treatments for Metastatic Bone Disease

Mavrogenis

Angelini

Vottis

et al. 2016

The Clinical Journal of Pain

Self Cite

View full text Add to dashboard Cite

Currently, modern treatments are available for the palliative management of patients with metastatic bone disease. These include modern radiation therapy, chemotherapy, embolization, electrochemotherapy, radiofrequency ablation, and high-intensity focused ultrasound. As such it is of interest for all physicians with no experience with these developments to make palliative procedures safer and more reliable.

show abstract

“…However, this palliative effect is transient; symptoms recurred after 8.1 months [37][38]. However, this palliative effect is transient; symptoms recurred after 8.1 months [37][38].…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Palliative Embolizationmentioning

confidence: 99%

Section: Techniquementioning

confidence: 99%

See 2 more Smart Citations

Modern Palliative Treatments for Metastatic Bone Disease

Mavrogenis

Angelini

Vottis

et al. 2016

The Clinical Journal of Pain

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is, however, potential difficulty in precisely delivering these particles through small microcatheters or through tortuous anatomy . For these reasons, some operators favour liquid agents such as N‐butyl 2‐cyanoacrylate for a more controlled and permeative delivery . Sun et al .…”

Section: Technique and Embolic Agentsmentioning

confidence: 99%

Embolisation of hypervascular bone tumours: A pictorial essay with literature review

2012

View full text Add to dashboard Cite

SummaryBone tumours, either primary or secondary, can present in various debilitating manners, including pain and pathological fracture. The situation is particularly problematic when the tumours are hypervascular, and located in regions where a high risk of neurological compromise is anticipated during operation, such as in the spine or sacrum. In such situations, bone tumour embolisation is a useful and effective adjunctive treatment for reducing intra-operative blood loss. This is particularly relevant in primary bone tumours such as giant cell tumours and metastatic renal cell and thyroid tumours. With a proper pre-embolisation angiogram and knowledge of anatomy, careful selective cannulation of the arterial supplies and experience in using embolic agents, the risks of non-target embolisation can be kept to minimum and the best result achieved.

show abstract

Reoperation after surgery for bone metastasis of renal cell carcinoma

Tsukamoto,

Aiba,

Zuccheri

et al. 2023

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Background and ObjectiveThe prognosis of metastatic renal cell carcinoma (RCC) has markedly improved with the advent of molecular targeted therapies and immune checkpoint inhibitors. However, the therapeutic response in patients with bone metastasis remains low; therefore, surgery still plays a significant role in treatment of bone metastasis. It is important to maintain quality of life for patients with bone metastasis from RCC and avoid reoperation after surgery for bone metastasis. Therefore, we investigated the risk factors for reoperation after surgery in patients with bone metastasis from RCC.MethodsWe retrospectively studied 103 bones of 97 patients who underwent surgery for bone metastasis of RCC from 2001 to 2023 at our institutions.ResultsReoperation was performed in 10 (9.7%) of 103 bones. There was no correlation between reoperation‐free survival and any of the following variables: preoperative and postoperative radiotherapy, site of bone metastasis, indication for surgery (solitary bone metastasis or impending or pathologic fractures), surgical method (intramedullary nailing fixation, curettage, or en bloc resection), preoperative embolization, or survival.ConclusionThe risk of reoperation for bone metastasis of RCC does not appear to be based on the surgical method.

show abstract

Selective Embolization with N-butyl Cyanoacrylate for Metastatic Bone Disease

Cited by 47 publications

References 32 publications

Modern Palliative Treatments for Metastatic Bone Disease

Modern Palliative Treatments for Metastatic Bone Disease

Embolisation of hypervascular bone tumours: A pictorial essay with literature review

Reoperation after surgery for bone metastasis of renal cell carcinoma

Contact Info

Product

Resources

About